Medications Development for the Treatment of Amphetamine and Amphetamine-Like Related Disorders (R21)

The summary for the Medications Development for the Treatment of Amphetamine and Amphetamine-Like Related Disorders (R21) Federal Grant is detailed below. It contains information such as the Catalog of Federal Domestic Assistance (CFDA) number, who is eligible for the grant, how much grant money will be awarded, important deadlines, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed in the Grant Announcement Contact section. If these sections are incomplete, please visit the website of the government agency that is offering this grant.


	Federal Grant Title:	Medications Development for the Treatment of Amphetamine and Amphetamine-Like Related Disorders (R21)
	CFDA Number:	93.279
	CFDA Description:	Drug Abuse and Addiction Research Programs
	Federal Agency Name:	National Institutes of Health
	Category of Funding Activity:	Education Health
	Category Explanation:	Information not provided
	Opportunity Category:	Discretionary
	Funding Opportunity Number:	PA-07-334
	Document Type:	Grants Notice
	Funding Instrument Type:	Grant
	Posted Date:	Mar 22, 2007
	Creation Date:	Dec 05, 2008
	Original Closing Date for Applications:	Multiple Receipt Dates - See Link to Full Announcement for details.
	Current Closing Date for Applications:	Multiple Receipt Dates - See Link to Full Announcement for details.
	Archive Date:	Jun 07, 2010
	Expected Number of Awards:	Information not provided
	Estimated Total Program Funding:	Information not provided
	Federal Grant Award Ceiling:	Information not provided
	Federal Grant Award Floor:	Information not provided
	Cost Sharing or Matching Requirement:	No

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility: Foreign institutions are eligible to apply. Eligible agencies of the Federal Government can apply. Faith-based or community-based organizations can apply.
Grant Description: Purpose. The goal of this program announcement is to encourage preclinical and clinical research directed towards the identification, evaluation and development of safe and effective medications for the treatment of Amphetamine and Amphetamine-like Related Disorders (ARDs), most importantly methamphetamine abuse and methamphetamine dependence. According to the DSM-IV-TR, the class of amphetamine and amphetamine-like substances includes all substances with a substituted-phenylethylamine structure, such as amphetamine, dextroamphetamine, methamphetamine, and MDMA (3,4-methylenedioxymethamphetamine). Also included are those substances that are structurally different but have amphetamine-like action, such as methylphenidate, some agents used as appetite suppressants, and khat. Amphetamines, amphetamine-like substances and methamphetamine especially, are highly addictive central nervous system stimulants that can be injected, snorted, smoked, or ingested orally. Of all the ARDs, prevalence data is most readily available for methamphetamine abuse and dependence. This data indicates that methamphetamine use continues to be a major public health concern in the United States for all segments of the population. Methamphetamine is unique in that it can be easily manufactured in clandestine laboratories using store-bought materials and is the most prevalent synthetic drug manufactured in the United States. The ease of manufacturing methamphetamine and its highly addictive potential has caused the use of the drug to greatly increase throughout the Nation. The methamphetamine problem was originally concentrated in the West of the United States, but has since spread throughout almost every major metropolitan area in the country, due to the low cost, high availability, and addictive properties of this substance. There are currently no effective pharmacological treatments for ARDs and there has been limited research focused on the identification and development of medications to treat these disorders, as well as research on the health effects of chronic abuse. For these reasons, the NIDA is encouraging research in this area.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/pa-files/pa-07-334.html
Grant Announcement Contact: NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [FBOWebmaster@OD.NIH.GOV]
Similar Government Grants: • FY12 NIDA Avant-Garde Award Program for HIV/AIDS Research (DP1); • Pre-Application for the FY12 NIDA Avant-Garde Award Program for HIV/AIDS Research (X02); • Pre-Application for the 2012 NIDA Translational Avant-Garde Award for Medication Development for the...; • 2012 NIDA Translational Avant-Garde Award for Medication Development for the Treatment of Substance ...; • International Tobacco and Health Research and Capacity Building Program (R01); • NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards; • DRUG ABUSE ASPECTS OF HIV/AIDS AND OTHER INFECTIONS; • EPIDEMIOLOGY OF DRUG ABUSE; • PRESCRIPTION DRUG ABUSE; • MDMA: RESEARCH AREAS NEEDING MORE EMPHASIS